SARS-CoV-2 is the causative agent of the COVID-19 pandemic. The approval of vaccines
and small-molecule antivirals is vital in combating the pandemic. The viral polymerase …

The increased prevalence of obesity, diabetes, and cardiovascular risk factors in people
hospitalized with severe COVID-19 illness has engendered considerable interest in the …

The nucleoside analog remdesivir (RDV) is a Food and Drug Administration–approved
antiviral for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

BACKGROUND: The coronavirus disease 2019 pandemic continues to affect millions
worldwide. Given the rapidly growing evidence base, we implemented a living guideline …

The main protease (Mpro, 3CLpro) of SARS-CoV-2 is an attractive target in coronaviruses
because of its crucial involvement in viral replication and transcription. Here, we report on …

Here, we report the synthesis, structure–activity relationship studies, enzyme inhibition,
antiviral activity, and X-ray crystallographic studies of 5-chloropyridinyl indole carboxylate …

Abstract Emerging from Wuhan, China, SARS-CoV-2 is the new global threat that killed
millions of people, and many are still suffering. This pandemic has not only affected people …

The most advanced antiviral molecules addressing major SARS-CoV-2 targets (Main
protease, Spike protein, and RNA polymerase), compared with proteins of other human …

Drug-induced liver injury (DILI) remains an important, yet challenging diagnosis for
physicians. Each year, additional drugs are implicated in DILI and this year was no different …

In this manuscript, we discuss the expectations versus the real-world results of four
repurposed COVID-19 drugs: tocilizumab, remdesivir, favipiravir, and dexamethasone from …